Skip to main content
Premium Trial:

Request an Annual Quote

NYDOH Approves AltheaDx's PGx Test Suite

NEW YORK (GenomeWeb) – AltheaDx's suite of pharmacogenetic tests, called IDgenetix, has been approved by the New York Department of Health, enabling the molecular diagnostics firm to sell the tests in all 50 US states.

AltheaDx performs all its tests out of its CLIA-certified San Diego laboratory, which in July also received accreditation from the College of American Pathologists.

The firm's IDgenetix tests gauge variations in CYP450 genes and determine whether patients are extensive, poor, intermediate, or ultra-rapid metabolizers. The tests produce a color-coded report for doctors indicating which drugs can be "used as directed" and which require caution or increased monitoring. The report also provides gene-specific results to the doctor to help them with therapeutic decisions for a number of cardiology, psychiatry, and pain management conditions.

The NYSDOH has one of the highest bars among state health departments for ensuring the safety and efficacy CLIA lab tests. During the review process, the NYSDOH looked over AltheaDx's test validation data, requisition forms, reports, as well as lab procedures and manuals. "The process also included an on-site inspection of the AltheaDx laboratory, which was completed with no deficiencies," the company said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more